Skip to main content

Market Overview

A Deeper Look Into Valeant's Assets As It Searches For Salix Buyer

Share:
A Deeper Look Into Valeant's Assets As It Searches For Salix Buyer

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is reportedly shopping for buyers to acquire its Salix unit for an expected $8.5 billion and additional royalty payments in the future.

Valeant is plagued with debt, causing some concern among shareholders so any cash infusion would certainly ease concern and be a net positive for the troubled company. On the other hand, investors have reason to be concerned that Valeant is divesting a business unit which is vital to its future.

Salix is a leader in the gastrointestinal market, which is one of a handful units Valeant operates.

Based on Valeant's second-quarter earnings results, the company's Gastrointestinal unit is the second largest segment based on revenue, which totaled $344.1 million. The largest business segment, neuro & other/generics collected $467.4 million in revenue in the quarter.

Here is a rundown of the remaining segments, based on their U.S. revenue.

  • Dermatology: $208.4 million.
  • Consumer: $173.1 million.
  • Ophthalmology Rx: $101.7 million.
  • Urology/Oncology: $77.5 million.
  • Surgical: $60.5 million.
  • Contact Lenses: $55.3 million.
  • Dental: $44.9 million.

What Could These Be Worth?

Valeant is negotiating from a position of weakness and not strength, so any sale would come at a depressed multiple, at least according to CIBC World Markets' analyst Prakash Gowd, who commented on any asset sale back in April.

Gowd suggested Valeant could receive a multiple of 6x EBITDA on an asset sale, which would value Xifaxan, Valeant's top-selling product for the treatment of irritable-bowel disease at just $3 billion.

The opportunity to collect a quick cash infusion to pay down some debt does not justify the lost earnings and cash flow, the analyst suggested.

Moving on, selling the neuro & other/generics segment is "not a great option since the resulting cash is less, and the de-leveraging opportunity even less impactful."

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX

View the Latest Analyst Ratings

 

Related Articles (VRX)

View Comments and Join the Discussion!

Posted-In: Gastrointestinal Drugs Prakash GowdAnalyst Color Biotech News Health Care Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com